Clinical Trial Update: Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 study assessing safety, tolerability, efficacy, and optimal dosing of BAF312 in relapsing-remitting multiple sclerosis has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• BAF312 (siponimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2020-01-13